制剂组成对抗表皮生长因子单克隆抗体稳定性的影响
({{custom_author.role_cn}}), {{javascript:window.custom_author_cn_index++;}}Effect of formulation components on stability of anti-EGF monoclonal antibody
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
